Skip to main content

28.11.2018 | Original Article

Dosimetry, biodistribution, and safety of flurpiridaz F 18 in healthy subjects undergoing rest and exercise or pharmacological stress PET myocardial perfusion imaging

verfasst von: Jamshid Maddahi, MD, FACC, FASNC, Frank Bengel, MD, Johannes Czernin, MD, Paul Crane, PhD, Magnus Dahlbom, PhD, Heinrich Schelbert, MD, PhD, Richard Sparks, PhD, Michael Phelps, PhD, Joel Lazewatsky, PhD

Erschienen in: Journal of Nuclear Cardiology

Einloggen, um Zugang zu erhalten

Abstract

The objectives of this study were to evaluate radiation dosimetry, biodistribution, human safety, and tolerability of 18F-labeled flurpiridaz (Flurpiridaz) in normal subjects undergoing rest and separate-day exercise or adenosine pharmacological stress PET imaging.

Methods

12 normal subjects were injected with 58.5 to 121 MBq (1.58 to 3.27 mCi) of Flurpiridaz intravenously at rest on Day 1 and 57 to 171 MBq (1.54 to 4.61 mCi) during stress on Day 2. Sequential whole-body imaging was performed for 5 hours. Blood samples were collected for up to 8 hours.

Results

The heart wall received the largest mean absorbed dose with both exercise and adenosine stresses. The mean effective dose was 0.054 rem/mCi (0.015 mSv/MBq) with exercise and 0.069 rem/mCi (0.019 mSv/MBq) with adenosine pharmacological stress. The maximum dose that may be administered without exceeding 1 rem (10 mSv) effective dose was 19 mCi (685 MBq) for exercise and 15 mCi (539 MBq) for adenosine pharmacological stress. There were no drug-related adverse events, and the tracer was well tolerated in all subjects.

Conclusion

Based on radiation dosimetry, biodistribution, and safety observations, 18F-labeled flurpiridaz is found suitable for clinical PET myocardial perfusion imaging in conjunction with either exercise or pharmacological stress testing.
Literatur
1.
Zurück zum Zitat Yalamanchili P, Wexler E, Hayes M, et al. Mechanism of uptake and retention of 18F BMS747158-02 in cardiomyocytes: A novel PET myocardial imaging agent. J Nucl Cardiol 2007;14:782-8.CrossRef Yalamanchili P, Wexler E, Hayes M, et al. Mechanism of uptake and retention of 18F BMS747158-02 in cardiomyocytes: A novel PET myocardial imaging agent. J Nucl Cardiol 2007;14:782-8.CrossRef
2.
Zurück zum Zitat Barth E, Stammler G, Speiser B, Schaper J. Ultrastuctural quantitation of mitochondria and myofilaments in cardiac muscle from 10 different animal species including man. J Mol Cell Cardiol 1992;24:669-81.CrossRef Barth E, Stammler G, Speiser B, Schaper J. Ultrastuctural quantitation of mitochondria and myofilaments in cardiac muscle from 10 different animal species including man. J Mol Cell Cardiol 1992;24:669-81.CrossRef
3.
Zurück zum Zitat Yu M, Guaraldi MT, Mistry M, et al. BMS747158-02: A novel PET myocardial perfusion imaging agent. J Nucl Cardiol 2007;14:789-98.CrossRef Yu M, Guaraldi MT, Mistry M, et al. BMS747158-02: A novel PET myocardial perfusion imaging agent. J Nucl Cardiol 2007;14:789-98.CrossRef
4.
Zurück zum Zitat Huisman M, Higuchi T, Reder S, et al. Initial characterization of an 18F-labeled myocardial perfusion tracer. J Nucl Med 2008;49:630-6.CrossRef Huisman M, Higuchi T, Reder S, et al. Initial characterization of an 18F-labeled myocardial perfusion tracer. J Nucl Med 2008;49:630-6.CrossRef
5.
Zurück zum Zitat Nekolla SG, Reder S, Higuchi T, et al. Evaluation of the novel myocardial perfusion PET tracer 18F-BMS747158-02: Comparison to 13N ammonia and validation with microspheres in a pig model. Circulation 2009;119:2333-42.CrossRef Nekolla SG, Reder S, Higuchi T, et al. Evaluation of the novel myocardial perfusion PET tracer 18F-BMS747158-02: Comparison to 13N ammonia and validation with microspheres in a pig model. Circulation 2009;119:2333-42.CrossRef
6.
Zurück zum Zitat Maddahi J, Czernin J, Lazewatsky J, Huang S-C, Dahlbom M, Schelbert HS, Sparks R, Ehlgen A, Crane P, Zhu Q, Devine M, Phelps M. Phase I, first-in-human study of BMS747158, a novel F-18 labeled tracer for myocardial perfusion PET imaging: Dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest. J Nucl Med 2011;52:1490-8.CrossRef Maddahi J, Czernin J, Lazewatsky J, Huang S-C, Dahlbom M, Schelbert HS, Sparks R, Ehlgen A, Crane P, Zhu Q, Devine M, Phelps M. Phase I, first-in-human study of BMS747158, a novel F-18 labeled tracer for myocardial perfusion PET imaging: Dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest. J Nucl Med 2011;52:1490-8.CrossRef
7.
Zurück zum Zitat International Commission on Radiological Protection (ICRP), Recommendations of the International Commission on Radiological Protection, Publication 60, Ann ICRP; 1990, 21, pp. 7-9. International Commission on Radiological Protection (ICRP), Recommendations of the International Commission on Radiological Protection, Publication 60, Ann ICRP; 1990, 21, pp. 7-9.
8.
Zurück zum Zitat Stabin MG, Sparks RB, et al. OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46:1023-7.PubMed Stabin MG, Sparks RB, et al. OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46:1023-7.PubMed
9.
Zurück zum Zitat Siegel JA, Thomas SR, Stubbs JB, et al. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999;40:37S-61S.PubMed Siegel JA, Thomas SR, Stubbs JB, et al. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999;40:37S-61S.PubMed
10.
Zurück zum Zitat International Commission on Radiological Protection (ICRP), Basic Anatomical & Physiological Data for use in Radiological Protection—The Skeleton, Publication 70; 1995, Ann ICRP, 21, p. 66. International Commission on Radiological Protection (ICRP), Basic Anatomical & Physiological Data for use in Radiological Protection—The Skeleton, Publication 70; 1995, Ann ICRP, 21, p. 66.
11.
Zurück zum Zitat Jones SC, Alavi A, Christman D, Montanez I, Wolf AP, Reivich M. The radiation dosimetry of 2 [F-18]fluoro-2-deoxy-D-glucose in man. J Nucl Med 1982;23:613-7.PubMed Jones SC, Alavi A, Christman D, Montanez I, Wolf AP, Reivich M. The radiation dosimetry of 2 [F-18]fluoro-2-deoxy-D-glucose in man. J Nucl Med 1982;23:613-7.PubMed
12.
Zurück zum Zitat Holly TA, Abbott BG, Al-Mallah M, et al. ASNC imaging guidelines for nuclear cardiology procedures—single photon emission computed tomography. J Nucl Cardiol 2010;17:941-73.CrossRef Holly TA, Abbott BG, Al-Mallah M, et al. ASNC imaging guidelines for nuclear cardiology procedures—single photon emission computed tomography. J Nucl Cardiol 2010;17:941-73.CrossRef
13.
Zurück zum Zitat Dilsizian V, Bacharach SL, Beanlands RS, et al. ASNC Imaging Guidelines for Nuclear Cardiology Procedures—PET myocardial perfusion and glucose metabolism clinical imaging. J Nucl Cardiol 2009;16:651-81.CrossRef Dilsizian V, Bacharach SL, Beanlands RS, et al. ASNC Imaging Guidelines for Nuclear Cardiology Procedures—PET myocardial perfusion and glucose metabolism clinical imaging. J Nucl Cardiol 2009;16:651-81.CrossRef
14.
Zurück zum Zitat Senthamizhchelvan S, Bravo PE, Esaias C, et al. Human biodistribution and radiation dosimetry of 82Rb. J Nucl Med 2010;51:1592-9.CrossRef Senthamizhchelvan S, Bravo PE, Esaias C, et al. Human biodistribution and radiation dosimetry of 82Rb. J Nucl Med 2010;51:1592-9.CrossRef
15.
Zurück zum Zitat Senthamizhchelvan S, Bravo PE, Lodge MA. Radiation dosimetry of 82Rb in humans under pharmacologic stress. J. Nucl Med 2011;52:485-91.CrossRef Senthamizhchelvan S, Bravo PE, Lodge MA. Radiation dosimetry of 82Rb in humans under pharmacologic stress. J. Nucl Med 2011;52:485-91.CrossRef
16.
Zurück zum Zitat International Commission on Radiological Protection (ICRP), Radiation Dose to Patients from Radiopharmaceutcals (Addendum to ICRP Publication 53), Publication 80, Ann ICRP; 1999, 28, p. 23. International Commission on Radiological Protection (ICRP), Radiation Dose to Patients from Radiopharmaceutcals (Addendum to ICRP Publication 53), Publication 80, Ann ICRP; 1999, 28, p. 23.
17.
Zurück zum Zitat International Commission on Radiological Protection (ICRP), Radiation Dose to Patients from Radiopharmaceuticals (Addendum to ICRP Publication 53), Publication 80, Ann ICRP, 1999, 28, pp. 109-10. International Commission on Radiological Protection (ICRP), Radiation Dose to Patients from Radiopharmaceuticals (Addendum to ICRP Publication 53), Publication 80, Ann ICRP, 1999, 28, pp. 109-10.
18.
Zurück zum Zitat International Commission on Radiological Protection (ICRP), Radiation Dose to Patients from Radiopharmaceuticals, Publication 53, Ann ICRP, 1987, 18, pp. 61-2. International Commission on Radiological Protection (ICRP), Radiation Dose to Patients from Radiopharmaceuticals, Publication 53, Ann ICRP, 1987, 18, pp. 61-2.
19.
Zurück zum Zitat Jentzen W, Weise R, Kupferschläger J, Freudenberg L, Brandau W, Bares R, Burchert W, Bockisch A. Iodine-124 PET dosimetry in differentiated thyroid cancer: Recovery coefficient in 2D and 3D modes for PET(/CT) systems. Eur J Nucl Med Mol Imaging 2008;35:611-23.CrossRef Jentzen W, Weise R, Kupferschläger J, Freudenberg L, Brandau W, Bares R, Burchert W, Bockisch A. Iodine-124 PET dosimetry in differentiated thyroid cancer: Recovery coefficient in 2D and 3D modes for PET(/CT) systems. Eur J Nucl Med Mol Imaging 2008;35:611-23.CrossRef
20.
Zurück zum Zitat Gould KL. Noninvasive assessment of coronary stenoses by myocardial perfusion imaging during pharmacologic coronary vasodilatation. I. Physiologic basis and experimental validation. Am J Cardiol 1978;41:267-78.CrossRef Gould KL. Noninvasive assessment of coronary stenoses by myocardial perfusion imaging during pharmacologic coronary vasodilatation. I. Physiologic basis and experimental validation. Am J Cardiol 1978;41:267-78.CrossRef
21.
Zurück zum Zitat Josephson MA, Brown BG, Hecht HS, Hopkins J, Pierce CD, Petersen RB. Noninvasive detection and localization of coronary stenoses in patients: Comparison of resting dipyridamole and exercise thallium-201 myocardial perfusion imaging. Am Heart J 1982;103:1008-18.CrossRef Josephson MA, Brown BG, Hecht HS, Hopkins J, Pierce CD, Petersen RB. Noninvasive detection and localization of coronary stenoses in patients: Comparison of resting dipyridamole and exercise thallium-201 myocardial perfusion imaging. Am Heart J 1982;103:1008-18.CrossRef
22.
Zurück zum Zitat Hunter C, Ziadi M, Etele J, Hill J, Beanlands R, deKemp R. New effective dose estimates for Rubidium-82 based on dynamic PET/CT imaging in humans. J Nucl Med 2010;51:1429. Hunter C, Ziadi M, Etele J, Hill J, Beanlands R, deKemp R. New effective dose estimates for Rubidium-82 based on dynamic PET/CT imaging in humans. J Nucl Med 2010;51:1429.
23.
Zurück zum Zitat Case J, Maddahi J, Bengel F, Bateman T, Dahlbom M, Lazewatsky J. Imaging properties of F-18 labeled myocardial perfusion PET agent, BMS747158: Dosage, acquisition time, and scanner type. J Nucl Med 2009;50:109. Case J, Maddahi J, Bengel F, Bateman T, Dahlbom M, Lazewatsky J. Imaging properties of F-18 labeled myocardial perfusion PET agent, BMS747158: Dosage, acquisition time, and scanner type. J Nucl Med 2009;50:109.
24.
Zurück zum Zitat Berman DS, Maddahi J, Tamarappoo BK, Czernin J, Taillefer R, Udelson JE, Gibson CM, Devine M, Lazewatsky J, Bhat G, Washburn D. Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: Flurpiridaz F 18 positron emission tomography. J Am Coll Cardiol 2013;61:469-77.CrossRef Berman DS, Maddahi J, Tamarappoo BK, Czernin J, Taillefer R, Udelson JE, Gibson CM, Devine M, Lazewatsky J, Bhat G, Washburn D. Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: Flurpiridaz F 18 positron emission tomography. J Am Coll Cardiol 2013;61:469-77.CrossRef
25.
Zurück zum Zitat Maddahi J, Udelson J, Heller GV, Lazewatsky JL, Orlandi C. The first phase 3 international multicenter clinical trial of Flurpiridaz F18, a new radiopharmaceutical for PET Myocardial perfusion imaging (abstract). J Nucl Cardiol 2015;22:744.CrossRef Maddahi J, Udelson J, Heller GV, Lazewatsky JL, Orlandi C. The first phase 3 international multicenter clinical trial of Flurpiridaz F18, a new radiopharmaceutical for PET Myocardial perfusion imaging (abstract). J Nucl Cardiol 2015;22:744.CrossRef
Metadaten
Titel
Dosimetry, biodistribution, and safety of flurpiridaz F 18 in healthy subjects undergoing rest and exercise or pharmacological stress PET myocardial perfusion imaging
verfasst von
Jamshid Maddahi, MD, FACC, FASNC
Frank Bengel, MD
Johannes Czernin, MD
Paul Crane, PhD
Magnus Dahlbom, PhD
Heinrich Schelbert, MD, PhD
Richard Sparks, PhD
Michael Phelps, PhD
Joel Lazewatsky, PhD
Publikationsdatum
28.11.2018
Verlag
Springer International Publishing
Erschienen in
Journal of Nuclear Cardiology
Print ISSN: 1071-3581
Elektronische ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-018-01484-z

Degenerierte Bioklappe: Ist Reoperation oder TAVI hier die bessere Option?

13.06.2024 TAVI Nachrichten

Im Fall eines Bioprothesen-Versagens nach Aortenklappenersatz kann ein notwendiger Revisionseingriff heute operativ oder kathetergestützt als Valve-in-Valve-TAVI vorgenommen werden. Eine Beobachtungsstudie lieferte neue Daten zum Vergleich beider Optionen.

TAVI bei kleinem Aortenklappenanulus: Es gibt noch ungeklärte Fragen

13.06.2024 TAVI Nachrichten

Zwischen selbstexpandierenden und ballonexpandierbaren TAVI-Klappen scheinen bezüglich der Klappenfunktion bei Aortenstenose und kleinem Aortenklappenanulus Unterschiede zu bestehen. Aber sind die überhaupt von klinischer Relevanz? Eine neue Studie liefert dazu Informationen.

Exazerbationen der COPD bedrohen auch das Herz

12.06.2024 COPD-Exazerbation Nachrichten

Kardiovaskuläre Erkrankungen sind die häufigsten Komorbiditäten von Patienten mit COPD. Exazerbationen der Lungenkrankheit bedrohen Herz und Gefäße aber auch ohne bereits bestehendes Begleitleiden, wie eine Studie zeigt.

Vorhofflimmern: Adipöse Patienten profitieren von dualer Kardioversion

11.06.2024 Vorhofflimmern Nachrichten

Bei stark übergewichtigen Personen lässt sich Vorhofflimmern mit zwei gleichzeitigen Schocks und einer insgesamt höheren Schockenergie effektiver stoppen als mit der herkömmlichen Single-Kardioversion, und das ohne höheres Komplikationsrisiko.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.